A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants - Trial NCT06362642
Access comprehensive clinical trial information for NCT06362642 through Pure Global AI's free database. This Phase 1 trial is sponsored by PMV Pharmaceuticals, Inc and is currently Recruiting. The study focuses on Healthy Volunteers. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
PMV Pharmaceuticals, Inc
Timeline & Enrollment
Phase 1
Mar 28, 2024
Dec 01, 2024
Primary Outcome
Characterize the Maximum Plasma Concentration (Cmax) of PC14586 when co-administered with itraconazole in healthy participants.,Characterize the total drug exposure (AUC0-inf) of PC14586 when co-administered with itraconazole in healthy participants.,Characterize the time to peak drug concentration (Tmax) of PC14586 when co-administered with itraconazole in healthy participants.,Characterize the total drug exposure from time zero to 24 hours (AUC0-24) of PC14586 when co-administered with itraconazole in healthy participants.,Characterize the total drug exposure from time zero to the last timepoint (AUC0-t) of PC14586 when co-administered with itraconazole in healthy participants.,Characterize the half-life (t1/2) of PC14586 when co-administered with itraconazole in healthy participants.
Summary
The purpose of this study is to assess the effect of PC14586 pharmacokinetics when co
 administered with itraconazole in healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06362642
Non-Device Trial